What are the precautions for Bosutinib?

Bosutinib is an oral dual Src/Abl inhibitor suitable for treatment

Bosutinib(Bosutinib)What are the precautions?

1.Gastrointestinal toxicity. Diarrhea, nausea, vomiting, and abdominal pain may occur with treatment with bosutinib. Monitor and manage patients using standard of care, including antidiarrheal medications, antiemetics, and fluid replacement. To control gastrointestinal toxicity, suspend, reduce the dose, or discontinue bosutinib if necessary.

2.Myelosuppression. Thrombocytopenia, anemia, and neutropenia may occur with bosutinibtreatment. Complete blood counts should be performed weekly during the first month of treatment and monthly thereafter, or as clinically indicated. To control myelosuppression, bosutinib may be suspended, dose reduced, or discontinued if necessary.

3.Hepatotoxicity. Bosutinib may cause an increase in serum aminotransferases (Alanine aminotransferase[ALT], aspartate aminotransferase[AST]). During the first 3 months of bosutinib treatment, liver enzyme tests were performed monthly as clinically indicated. Liver enzymes should be monitored more frequently in patients with elevated transaminases. If necessary, suspend, reduce dose, or discontinue bosutinib.

4.Cardiovascular toxicity. Bosutinibcan cause cardiovascular toxicities, including heart failure, left ventricular dysfunction, and cardiac ischemic events. Monitor patients for signs and symptoms consistent with heart failure and cardiac ischemia and treat as clinically indicated. If necessary, interrupt, reduce dose, or discontinue bosutinib.

5.Based on findings from animal studies and its mechanism of action, it may cause fetal harm when administered to pregnant women. If used during pregnancy or if the patient becomes pregnant while receiving the drug, inform patients of the potential fetal hazard.

6.It is unknown whether bosutinib or its metabolites distribute into breast milk, affect breastfed children, or affect milk production. Detected in the milk of lactating rats. Avoid breastfeeding during treatment and for ≥2 weeks after the last dose.

7.In females and males of reproductive potential, verify the pregnancy status of females of reproductive potential before initiating bosutinib treatment. Advise females of reproductive potential to use effective contraception during treatment with bosutinib and for ≥2 weeks after the last dose.

There are generic drugs in India, each box costs about 1 more than 1,000. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to learn more about high-quality overseas drugs for you.